4/28 Taiwan Life Sciences Weekly Newsletter
2025-04-28 |
| Taiwan Life Sciences Weekly |
| Taiwanese healthtech Dbio to set up European HQ in Luxembourg 25 April, 2025 The Taiwanese healthtech Decentralized Biotechnology Intelligence Group (Dbio) plans to set up its European headquarters in Luxembourg, along with an AI research centre that will serve as a hub for innovation in digital health and wearable technology, the company said at a press conference today, together with Luxinnovation CEO Mario Grotz. More... |
| Steminent Biotherapeutics releases Phase II clinical data for Taiwan-Japan trial on cerebellar atrophy 25 April, 2025 Steminent Biotherapeutics (TW: 7729) announced that it had presented Phase II clinical trial results of its stem cell drug Stemchymal for the first time at the World Orphan Drug Congress (WODC) in the US. The data confirmed that Stemchymal, developed for the treatment of spinocerebellar ataxia (SCA)--a form of cerebellar atrophy--demonstrated clear disease-relieving effects across different evaluation scales. Dr. Kontos, a clinical and scientific advisor with prior FDA leadership experience, presented the Phase II trial results of Stemchymal on behalf of Steminent. More... (in Chinese) |
| Kim Forest expands California operations, aims to be key enabler for Taiwanese US entry 24 April, 2025 Genetic testing company Kim Forest (TW: 6645) announced that its US subsidiary, Gene on Link LLC, has relocated and expanded its operations at a new laboratory in Los Angeles. The lab began offering local molecular testing, analysis, and whole genome sequencing services in April, aiming to capture business opportunities in the US. Kim Forest stated that this new lab will also serve as a demonstration center for Taiwanese brand testing instruments and reagents, providing sales and customer service support. More... (in Chinese) |
| Botanicure launches plant-based new drug platform, with focus on Alzheimer's drug development 24 April, 2025 Botanicure is actively expanding its plant-based new drug platform, focusing on the development of plant-derived drugs for Alzheimer's disease. The company announced that it has completed Phase IIa clinical trials approved by the US FDA and is now progressing toward Phase IIb trials. More... (in Chinese) |
| Primo Biotechnology's Taoyuan plant obtains PIC/S GMP certification 23 April, 2025 On April 23, Primo Biotechnology announced that its Taoyuan pharmaceutical plant has passed an inspection by the Taiwan FDA and has received dual certification, PIC/S GMP for sterile radiopharmaceuticals and PIC/S GDP for distribution practices. With this milestone, Primo officially enters the field of radiopharmaceutical manufacturing and supply, laying a crucial foundation for future drug development and international market expansion. More... (in Chinese) |
| U-Neuron Biomedical announces three major operational highlights 22 April, 2025 U-Neuron Biomedical (TW: 6973) recently held an investor conference where it announced three major operational highlights, including its allogeneic stem cell new drug UA002 entering Phase II clinical trials; the Deer Amniotic Fluid series products being sold through Christina's nearly 5,000 locations in China, Taiwan, and other regions starting in the second half of the year; and the development of various deer antler exosome product applications, as well as entering Malaysia. U-Neuron Biomedical's UA002 is targeting erectile dysfunction (ED) ineffective to oral medications. More... (in Chinese) |
| AmCad BioMed establishes demonstration center in Dubai, introducing sleep apnea system 22 April, 2025 AmCad BioMed (TW: 4188) announced that it has partnered with GluCare, a well-known clinic in Dubai, to establish a Middle East demonstration center and introduce its AI sleep apnea detection system. This marks the second collaboration between the two parties.. More... (in Chinese) |
| AP Biosciences enrolls first subject in Australian Phase I clinical trial for antibody drug AP402 22 April, 2025 AP Biosciences (TW: 6945) announced that its independently-developed bispecific antibody new drug AP402 has commenced clinical trials in Australia, with the first patient enrolled. This trial primarily targets patients with HER2-positive advanced solid tumors who have responded poorly to existing therapies, evaluating the safety and preliminary efficacy of AP402. The trial is expected to recruit up to 85 patients in two stages. Enrollment for the Phase I trial is expected to be completed in 2026. More... (in Chinese) |
| Drug review processes to be shortened, FDA says 22 April, 2025 New drug review processes would be accelerated and completed in 120 days in response to a US plan to raise pharmaceutical tariffs, the Ministry of Health and Welfare of Taiwan said yesterday. Food and Drug Administration (FDA) Deputy Director-General Wang Der-yuan yesterday told a news conference that measures have been taken to optimize new medicine review processes and help pharmaceutical companies obtain drug permit licenses as soon as possible. More... |
| Taipei Medical University and MSD launch collaboration to enhance healthcare innovation 21 April, 2025 Taipei Medical University (TMU) and Merck Sharp & Dohme (MSD) Taiwan have signed a Memorandum of Understanding to collaborate in six key directions aiming to advance healthcare in Taiwan. This partnership, the very first large-scale alliance between a global pharmaceutical company and a medical university in Taiwan, will inject international resources into the country's healthcare innovation ecosystem and enhance its biotechnology and pharmaceutical competitiveness. More... |
| BIO Asia-Taiwan Kicks Off on an Expanded Scale July 23 Press release 21 April, 2025 Co-organized by the Biotechnology Innovation Organization (BIO) and the Taiwan Bio Industry Organization (Taiwan BIO), BIO Asia Taiwan 2025 will be held July 23-27 at TaiNEX 1 & 2, Nangang Exhibition Center, Taipei. Building on last year's focus on innovation, investment, and regional collaboration, the gathering is expected to draw biotech professionals from more than 50 countries. The exhibition will feature over 900 leading companies occupying 2,200+ booths. New to the program this year is the Demo Day along with site visits to some of Taiwan's leading biomedical parks, extending the overall program to nine days. More... |
| Aiming for precision cancer medicine: Roche and TTY Biopharm join forces 19 April, 2025 Aiming for precision cancer medicine business opportunities, Roche Pharmaceuticals' Taiwan office and TTY Biopharm (TW: 4105) have signed a collaboration agreement, with Roche's innovative oral targeted cancer drug Rozlytrek being licensed to TTY Biopharm, while Roche will continue to provide clinical trial and related research support. More... (in Chinese) |
| A Pioneering Biotech Company Redefining Cell Therapy and Drug Discovery Platforms Promotional article 19 April, 2025 Taiwan's biotech industry is living its golden days, and LumiSTAR is certainly one of its shining examples. It all started at Oxford University, when LumiSTAR co-founders Yu-Fen Chang, CEO, and Min-Wen Chung, COO, were working on the development of a novel bioimaging technology for drug screening and clinical research. More... |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Contact: Daisy Tsai Tel: +886 2 27836028 ext 14 FAX : +886 2 27836027 Mobile: +886 933-139647 | Line ID : daisy222 Email: daisy@taiwanbio.org.tw BIO Asia-Taiwan 2025 (23-27 July, 2025) ========================================= Taiwan Bio Industry Organization (TBIO) Room C229, Bldg. C, No.99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |